IFNA1 and chronic hepatitis B virus infection: On the other hand, IFN-α and Peg-IFN-α, which are widely used to treat patients with chronic hepatitis B, have been shown to produce therapeutic effects of HBeAg-negative conversion or seroconversion (in HBeAg-positive patients), HBsAg clearance, HBV DNA-negative conversion, and ALT normalization [15-17].